nodes	percent_of_prediction	percent_of_DWPC	metapath
Cysteamine—MPO—Carboplatin—uterine cancer	0.541	1	CbGbCtD
Cysteamine—SST—artery—uterine cancer	0.028	0.187	CbGeAlD
Cysteamine—SST—exocrine gland—uterine cancer	0.0244	0.163	CbGeAlD
Cysteamine—SST—myometrium—uterine cancer	0.0135	0.0901	CbGeAlD
Cysteamine—MPO—artery—uterine cancer	0.0113	0.0751	CbGeAlD
Cysteamine—SST—epithelium—uterine cancer	0.0106	0.0708	CbGeAlD
Cysteamine—SST—smooth muscle tissue—uterine cancer	0.0102	0.0682	CbGeAlD
Cysteamine—SST—decidua—uterine cancer	0.01	0.0668	CbGeAlD
Cysteamine—SST—renal system—uterine cancer	0.00983	0.0656	CbGeAlD
Cysteamine—SST—endometrium—uterine cancer	0.00951	0.0634	CbGeAlD
Cysteamine—SST—female reproductive system—uterine cancer	0.00787	0.0526	CbGeAlD
Cysteamine—SST—Mecp2 and Associated Rett Syndrome—EZH2—uterine cancer	0.00503	0.0904	CbGpPWpGaD
Cysteamine—SST—lymph node—uterine cancer	0.00461	0.0307	CbGeAlD
Cysteamine—MPO—epithelium—uterine cancer	0.00427	0.0285	CbGeAlD
Cysteamine—MPO—renal system—uterine cancer	0.00396	0.0264	CbGeAlD
Cysteamine—NPY2R—Circadian rythm related genes—STAR—uterine cancer	0.00293	0.0527	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—HNF1B—uterine cancer	0.00239	0.043	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.00197	0.0354	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—SOCS3—uterine cancer	0.00194	0.0349	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—GPX3—uterine cancer	0.00191	0.0344	CbGpPWpGaD
Cysteamine—MPO—lymph node—uterine cancer	0.00186	0.0124	CbGeAlD
Cysteamine—SST—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.00182	0.0326	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—EZH2—uterine cancer	0.00153	0.0276	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—GPX3—uterine cancer	0.00152	0.0273	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Progesterone—uterine cancer	0.0013	0.00513	CcSEcCtD
Cysteamine—Connective tissue disorder—Progesterone—uterine cancer	0.00129	0.00511	CcSEcCtD
Cysteamine—Urethral disorder—Progesterone—uterine cancer	0.00129	0.00509	CcSEcCtD
Cysteamine—Liver function test abnormal—Dactinomycin—uterine cancer	0.00124	0.0049	CcSEcCtD
Cysteamine—Optic neuritis—Epirubicin—uterine cancer	0.00122	0.00482	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—CCL2—uterine cancer	0.00122	0.0219	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—MTHFR—uterine cancer	0.00121	0.0217	CbGpPWpGaD
Cysteamine—Immune system disorder—Progesterone—uterine cancer	0.00119	0.00469	CcSEcCtD
Cysteamine—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.00118	0.00465	CcSEcCtD
Cysteamine—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00463	CcSEcCtD
Cysteamine—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00462	CcSEcCtD
Cysteamine—Mental disorder—Progesterone—uterine cancer	0.00115	0.00455	CcSEcCtD
Cysteamine—Erythema—Progesterone—uterine cancer	0.00115	0.00452	CcSEcCtD
Cysteamine—Malnutrition—Progesterone—uterine cancer	0.00115	0.00452	CcSEcCtD
Cysteamine—Optic neuritis—Doxorubicin—uterine cancer	0.00113	0.00446	CcSEcCtD
Cysteamine—Tension—Progesterone—uterine cancer	0.00112	0.00444	CcSEcCtD
Cysteamine—Blood alkaline phosphatase increased—Etoposide—uterine cancer	0.00112	0.00442	CcSEcCtD
Cysteamine—Redness—Epirubicin—uterine cancer	0.00111	0.0044	CcSEcCtD
Cysteamine—Nervousness—Progesterone—uterine cancer	0.00111	0.00439	CcSEcCtD
Cysteamine—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00108	0.00425	CcSEcCtD
Cysteamine—Tremor—Progesterone—uterine cancer	0.00107	0.00424	CcSEcCtD
Cysteamine—Anaemia—Progesterone—uterine cancer	0.00106	0.00418	CcSEcCtD
Cysteamine—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.00412	CcSEcCtD
Cysteamine—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.0041	CcSEcCtD
Cysteamine—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.0041	CcSEcCtD
Cysteamine—Redness—Doxorubicin—uterine cancer	0.00103	0.00407	CcSEcCtD
Cysteamine—Tension—Medroxyprogesterone Acetate—uterine cancer	0.00102	0.00402	CcSEcCtD
Cysteamine—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.00101	0.00398	CcSEcCtD
Cysteamine—Convulsion—Progesterone—uterine cancer	0.000992	0.00392	CcSEcCtD
Cysteamine—Scotoma—Epirubicin—uterine cancer	0.000989	0.00391	CcSEcCtD
Cysteamine—Hypertension—Progesterone—uterine cancer	0.000989	0.00391	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—MTHFR—uterine cancer	0.000982	0.0176	CbGpPWpGaD
Cysteamine—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.000972	0.00384	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000968	0.00382	CcSEcCtD
Cysteamine—Discomfort—Progesterone—uterine cancer	0.000963	0.0038	CcSEcCtD
Cysteamine—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.000959	0.00379	CcSEcCtD
Cysteamine—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.000954	0.00377	CcSEcCtD
Cysteamine—MPO—Vitamin B12 Metabolism—CCL2—uterine cancer	0.000944	0.017	CbGpPWpGaD
Cysteamine—Confusional state—Progesterone—uterine cancer	0.000942	0.00372	CcSEcCtD
Cysteamine—Anaphylactic shock—Progesterone—uterine cancer	0.000935	0.00369	CcSEcCtD
Cysteamine—Nervous system disorder—Progesterone—uterine cancer	0.000917	0.00362	CcSEcCtD
Cysteamine—Scotoma—Doxorubicin—uterine cancer	0.000915	0.00362	CcSEcCtD
Cysteamine—Skin disorder—Progesterone—uterine cancer	0.000908	0.00359	CcSEcCtD
Cysteamine—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.000899	0.00355	CcSEcCtD
Cysteamine—Anorexia—Progesterone—uterine cancer	0.000891	0.00352	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000877	0.00347	CcSEcCtD
Cysteamine—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000873	0.00345	CcSEcCtD
Cysteamine—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.000854	0.00337	CcSEcCtD
Cysteamine—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.000847	0.00335	CcSEcCtD
Cysteamine—Bone disorder—Epirubicin—uterine cancer	0.000832	0.00328	CcSEcCtD
Cysteamine—Somnolence—Progesterone—uterine cancer	0.000831	0.00328	CcSEcCtD
Cysteamine—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000831	0.00328	CcSEcCtD
Cysteamine—SST—Peptide ligand-binding receptors—CCL2—uterine cancer	0.000828	0.0149	CbGpPWpGaD
Cysteamine—Dyspepsia—Progesterone—uterine cancer	0.000823	0.00325	CcSEcCtD
Cysteamine—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000823	0.00325	CcSEcCtD
Cysteamine—Thinking abnormal—Epirubicin—uterine cancer	0.000821	0.00324	CcSEcCtD
Cysteamine—Decreased appetite—Progesterone—uterine cancer	0.000813	0.00321	CcSEcCtD
Cysteamine—Erythema—Dactinomycin—uterine cancer	0.000809	0.0032	CcSEcCtD
Cysteamine—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000807	0.00319	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Progesterone—uterine cancer	0.000807	0.00319	CcSEcCtD
Cysteamine—Fatigue—Progesterone—uterine cancer	0.000806	0.00318	CcSEcCtD
Cysteamine—Constipation—Progesterone—uterine cancer	0.000799	0.00316	CcSEcCtD
Cysteamine—NPY2R—Peptide ligand-binding receptors—CCL2—uterine cancer	0.000794	0.0143	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—MTHFR—uterine cancer	0.00078	0.014	CbGpPWpGaD
Cysteamine—Feeling abnormal—Progesterone—uterine cancer	0.00077	0.00304	CcSEcCtD
Cysteamine—Bone disorder—Doxorubicin—uterine cancer	0.00077	0.00304	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—CCL2—uterine cancer	0.000768	0.0138	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—CXCL8—uterine cancer	0.000767	0.0138	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Progesterone—uterine cancer	0.000764	0.00302	CcSEcCtD
Cysteamine—Thinking abnormal—Doxorubicin—uterine cancer	0.000759	0.003	CcSEcCtD
Cysteamine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000753	0.00297	CcSEcCtD
Cysteamine—Phosphatase alkaline increased—Epirubicin—uterine cancer	0.000751	0.00297	CcSEcCtD
Cysteamine—Anaemia—Dactinomycin—uterine cancer	0.000748	0.00295	CcSEcCtD
Cysteamine—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000746	0.00294	CcSEcCtD
Cysteamine—Urticaria—Progesterone—uterine cancer	0.000743	0.00293	CcSEcCtD
Cysteamine—Abdominal pain—Progesterone—uterine cancer	0.000739	0.00292	CcSEcCtD
Cysteamine—Body temperature increased—Progesterone—uterine cancer	0.000739	0.00292	CcSEcCtD
Cysteamine—Renal failure—Etoposide—uterine cancer	0.000737	0.00291	CcSEcCtD
Cysteamine—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000736	0.00291	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000731	0.00289	CcSEcCtD
Cysteamine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00073	0.00288	CcSEcCtD
Cysteamine—Leukopenia—Dactinomycin—uterine cancer	0.000725	0.00286	CcSEcCtD
Cysteamine—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000724	0.00286	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	0.000707	0.0127	CbGpPWpGaD
Cysteamine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000698	0.00276	CcSEcCtD
Cysteamine—Phosphatase alkaline increased—Doxorubicin—uterine cancer	0.000695	0.00275	CcSEcCtD
Cysteamine—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000693	0.00274	CcSEcCtD
Cysteamine—Hypersensitivity—Progesterone—uterine cancer	0.000689	0.00272	CcSEcCtD
Cysteamine—Discomfort—Dactinomycin—uterine cancer	0.000681	0.00269	CcSEcCtD
Cysteamine—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000673	0.00266	CcSEcCtD
Cysteamine—Asthenia—Progesterone—uterine cancer	0.000671	0.00265	CcSEcCtD
Cysteamine—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00067	0.00264	CcSEcCtD
Cysteamine—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00067	0.00264	CcSEcCtD
Cysteamine—Urinary tract disorder—Etoposide—uterine cancer	0.000665	0.00262	CcSEcCtD
Cysteamine—Urethral disorder—Etoposide—uterine cancer	0.00066	0.00261	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—EP300—uterine cancer	0.000658	0.0118	CbGpPWpGaD
Cysteamine—SST—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.000655	0.0118	CbGpPWpGaD
Cysteamine—Mental disability—Epirubicin—uterine cancer	0.000652	0.00257	CcSEcCtD
Cysteamine—Diarrhoea—Progesterone—uterine cancer	0.00064	0.00253	CcSEcCtD
Cysteamine—Anorexia—Dactinomycin—uterine cancer	0.00063	0.00249	CcSEcCtD
Cysteamine—NPY2R—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.000628	0.0113	CbGpPWpGaD
Cysteamine—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.000627	0.00248	CcSEcCtD
Cysteamine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000624	0.00246	CcSEcCtD
Cysteamine—Hepatic function abnormal—Epirubicin—uterine cancer	0.000624	0.00246	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—VEGFA—uterine cancer	0.000623	0.0112	CbGpPWpGaD
Cysteamine—Dizziness—Progesterone—uterine cancer	0.000618	0.00244	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—PIK3CA—uterine cancer	0.000612	0.011	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—CCL2—uterine cancer	0.00061	0.011	CbGpPWpGaD
Cysteamine—Immune system disorder—Etoposide—uterine cancer	0.000608	0.0024	CcSEcCtD
Cysteamine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000608	0.0024	CcSEcCtD
Cysteamine—Eye pain—Epirubicin—uterine cancer	0.000604	0.00239	CcSEcCtD
Cysteamine—Mental disability—Doxorubicin—uterine cancer	0.000603	0.00238	CcSEcCtD
Cysteamine—Vomiting—Progesterone—uterine cancer	0.000594	0.00235	CcSEcCtD
Cysteamine—Rash—Progesterone—uterine cancer	0.000589	0.00233	CcSEcCtD
Cysteamine—Dermatitis—Progesterone—uterine cancer	0.000589	0.00233	CcSEcCtD
Cysteamine—Headache—Progesterone—uterine cancer	0.000586	0.00231	CcSEcCtD
Cysteamine—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.00058	0.00229	CcSEcCtD
Cysteamine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00058	0.00229	CcSEcCtD
Cysteamine—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000577	0.00228	CcSEcCtD
Cysteamine—Decreased appetite—Dactinomycin—uterine cancer	0.000574	0.00227	CcSEcCtD
Cysteamine—Fatigue—Dactinomycin—uterine cancer	0.00057	0.00225	CcSEcCtD
Cysteamine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00056	0.00221	CcSEcCtD
Cysteamine—Eye pain—Doxorubicin—uterine cancer	0.000559	0.00221	CcSEcCtD
Cysteamine—Lethargy—Epirubicin—uterine cancer	0.000556	0.0022	CcSEcCtD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000556	0.00998	CbGpPWpGaD
Cysteamine—Nausea—Progesterone—uterine cancer	0.000555	0.00219	CcSEcCtD
Cysteamine—SST—G alpha (i) signalling events—CXCL8—uterine cancer	0.000552	0.00993	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—CDKN2A—uterine cancer	0.000552	0.00992	CbGpPWpGaD
Cysteamine—Pain in extremity—Epirubicin—uterine cancer	0.000545	0.00215	CcSEcCtD
Cysteamine—Feeling abnormal—Dactinomycin—uterine cancer	0.000544	0.00215	CcSEcCtD
Cysteamine—Anaemia—Etoposide—uterine cancer	0.000541	0.00214	CcSEcCtD
Cysteamine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00054	0.00213	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—PTEN—uterine cancer	0.00054	0.0097	CbGpPWpGaD
Cysteamine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000539	0.00213	CcSEcCtD
Cysteamine—Affect lability—Epirubicin—uterine cancer	0.000537	0.00212	CcSEcCtD
Cysteamine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000534	0.00211	CcSEcCtD
Cysteamine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000534	0.00211	CcSEcCtD
Cysteamine—SST—Signaling Pathways—AKR1B10—uterine cancer	0.000533	0.00958	CbGpPWpGaD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000533	0.00957	CbGpPWpGaD
Cysteamine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000531	0.0021	CcSEcCtD
Cysteamine—NPY2R—G alpha (i) signalling events—CXCL8—uterine cancer	0.00053	0.00952	CbGpPWpGaD
Cysteamine—Leukopenia—Etoposide—uterine cancer	0.000524	0.00207	CcSEcCtD
Cysteamine—Abdominal pain—Dactinomycin—uterine cancer	0.000522	0.00206	CcSEcCtD
Cysteamine—Body temperature increased—Dactinomycin—uterine cancer	0.000522	0.00206	CcSEcCtD
Cysteamine—Mood swings—Epirubicin—uterine cancer	0.000517	0.00204	CcSEcCtD
Cysteamine—Lethargy—Doxorubicin—uterine cancer	0.000515	0.00203	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—EP300—uterine cancer	0.000515	0.00925	CbGpPWpGaD
Cysteamine—Ataxia—Epirubicin—uterine cancer	0.000513	0.00203	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—AKR1B10—uterine cancer	0.000511	0.00918	CbGpPWpGaD
Cysteamine—Convulsion—Etoposide—uterine cancer	0.000508	0.002	CcSEcCtD
Cysteamine—Dehydration—Epirubicin—uterine cancer	0.000507	0.002	CcSEcCtD
Cysteamine—Hypertension—Etoposide—uterine cancer	0.000506	0.002	CcSEcCtD
Cysteamine—Pain in extremity—Doxorubicin—uterine cancer	0.000505	0.00199	CcSEcCtD
Cysteamine—Liver function test abnormal—Epirubicin—uterine cancer	0.000503	0.00199	CcSEcCtD
Cysteamine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000503	0.00199	CcSEcCtD
Cysteamine—Affect lability—Doxorubicin—uterine cancer	0.000497	0.00196	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000495	0.00196	CcSEcCtD
Cysteamine—Discomfort—Etoposide—uterine cancer	0.000493	0.00195	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CDKN1B—uterine cancer	0.000489	0.00879	CbGpPWpGaD
Cysteamine—Hypersensitivity—Dactinomycin—uterine cancer	0.000487	0.00192	CcSEcCtD
Cysteamine—Confusional state—Etoposide—uterine cancer	0.000482	0.0019	CcSEcCtD
Cysteamine—Anaphylactic shock—Etoposide—uterine cancer	0.000478	0.00189	CcSEcCtD
Cysteamine—Mood swings—Doxorubicin—uterine cancer	0.000478	0.00189	CcSEcCtD
Cysteamine—Ataxia—Doxorubicin—uterine cancer	0.000474	0.00187	CcSEcCtD
Cysteamine—Asthenia—Dactinomycin—uterine cancer	0.000474	0.00187	CcSEcCtD
Cysteamine—Dehydration—Doxorubicin—uterine cancer	0.000469	0.00185	CcSEcCtD
Cysteamine—Liver function test abnormal—Doxorubicin—uterine cancer	0.000466	0.00184	CcSEcCtD
Cysteamine—Skin disorder—Etoposide—uterine cancer	0.000464	0.00183	CcSEcCtD
Cysteamine—Anorexia—Etoposide—uterine cancer	0.000456	0.0018	CcSEcCtD
Cysteamine—Diarrhoea—Dactinomycin—uterine cancer	0.000452	0.00179	CcSEcCtD
Cysteamine—SST—Signaling Pathways—RNF43—uterine cancer	0.000442	0.00793	CbGpPWpGaD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000439	0.00789	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—EP300—uterine cancer	0.00043	0.00772	CbGpPWpGaD
Cysteamine—Somnolence—Etoposide—uterine cancer	0.000425	0.00168	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—RNF43—uterine cancer	0.000423	0.00761	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—CCL2—uterine cancer	0.000423	0.0076	CbGpPWpGaD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000421	0.00757	CbGpPWpGaD
Cysteamine—Vomiting—Dactinomycin—uterine cancer	0.00042	0.00166	CcSEcCtD
Cysteamine—Rash—Dactinomycin—uterine cancer	0.000417	0.00165	CcSEcCtD
Cysteamine—Decreased appetite—Etoposide—uterine cancer	0.000416	0.00164	CcSEcCtD
Cysteamine—Renal failure—Epirubicin—uterine cancer	0.000413	0.00163	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000413	0.00163	CcSEcCtD
Cysteamine—Fatigue—Etoposide—uterine cancer	0.000412	0.00163	CcSEcCtD
Cysteamine—Constipation—Etoposide—uterine cancer	0.000409	0.00161	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—CCL2—uterine cancer	0.000406	0.00729	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—INHBA—uterine cancer	0.000404	0.00726	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—NRAS—uterine cancer	0.000402	0.00722	CbGpPWpGaD
Cysteamine—Feeling abnormal—Etoposide—uterine cancer	0.000394	0.00156	CcSEcCtD
Cysteamine—Nausea—Dactinomycin—uterine cancer	0.000392	0.00155	CcSEcCtD
Cysteamine—Gastrointestinal pain—Etoposide—uterine cancer	0.000391	0.00154	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—INHBA—uterine cancer	0.000387	0.00696	CbGpPWpGaD
Cysteamine—Renal failure—Doxorubicin—uterine cancer	0.000382	0.00151	CcSEcCtD
Cysteamine—Urticaria—Etoposide—uterine cancer	0.00038	0.0015	CcSEcCtD
Cysteamine—Abdominal pain—Etoposide—uterine cancer	0.000378	0.00149	CcSEcCtD
Cysteamine—Body temperature increased—Etoposide—uterine cancer	0.000378	0.00149	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—TP53—uterine cancer	0.000373	0.0067	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Epirubicin—uterine cancer	0.000373	0.00147	CcSEcCtD
Cysteamine—Connective tissue disorder—Epirubicin—uterine cancer	0.000371	0.00146	CcSEcCtD
Cysteamine—Urethral disorder—Epirubicin—uterine cancer	0.00037	0.00146	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—TP53—uterine cancer	0.000368	0.00662	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—AKR1C1—uterine cancer	0.000364	0.00653	CbGpPWpGaD
Cysteamine—Hypersensitivity—Etoposide—uterine cancer	0.000352	0.00139	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—AKR1C1—uterine cancer	0.000349	0.00626	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—KRAS—uterine cancer	0.000346	0.00621	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Doxorubicin—uterine cancer	0.000345	0.00136	CcSEcCtD
Cysteamine—Asthenia—Etoposide—uterine cancer	0.000343	0.00135	CcSEcCtD
Cysteamine—Connective tissue disorder—Doxorubicin—uterine cancer	0.000343	0.00135	CcSEcCtD
Cysteamine—Urethral disorder—Doxorubicin—uterine cancer	0.000342	0.00135	CcSEcCtD
Cysteamine—Immune system disorder—Epirubicin—uterine cancer	0.000341	0.00135	CcSEcCtD
Cysteamine—SST—GPCR ligand binding—CXCL8—uterine cancer	0.000335	0.00601	CbGpPWpGaD
Cysteamine—Mental disorder—Epirubicin—uterine cancer	0.000331	0.00131	CcSEcCtD
Cysteamine—Erythema—Epirubicin—uterine cancer	0.000328	0.0013	CcSEcCtD
Cysteamine—Malnutrition—Epirubicin—uterine cancer	0.000328	0.0013	CcSEcCtD
Cysteamine—Diarrhoea—Etoposide—uterine cancer	0.000327	0.00129	CcSEcCtD
Cysteamine—Tension—Epirubicin—uterine cancer	0.000322	0.00127	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—CXCL8—uterine cancer	0.000321	0.00576	CbGpPWpGaD
Cysteamine—Nervousness—Epirubicin—uterine cancer	0.000319	0.00126	CcSEcCtD
Cysteamine—Dizziness—Etoposide—uterine cancer	0.000316	0.00125	CcSEcCtD
Cysteamine—Immune system disorder—Doxorubicin—uterine cancer	0.000315	0.00125	CcSEcCtD
Cysteamine—Mental disorder—Doxorubicin—uterine cancer	0.000306	0.00121	CcSEcCtD
Cysteamine—Vomiting—Etoposide—uterine cancer	0.000304	0.0012	CcSEcCtD
Cysteamine—Erythema—Doxorubicin—uterine cancer	0.000304	0.0012	CcSEcCtD
Cysteamine—Malnutrition—Doxorubicin—uterine cancer	0.000304	0.0012	CcSEcCtD
Cysteamine—Anaemia—Epirubicin—uterine cancer	0.000304	0.0012	CcSEcCtD
Cysteamine—Agitation—Epirubicin—uterine cancer	0.000302	0.00119	CcSEcCtD
Cysteamine—Rash—Etoposide—uterine cancer	0.000301	0.00119	CcSEcCtD
Cysteamine—Dermatitis—Etoposide—uterine cancer	0.000301	0.00119	CcSEcCtD
Cysteamine—Headache—Etoposide—uterine cancer	0.0003	0.00118	CcSEcCtD
Cysteamine—Tension—Doxorubicin—uterine cancer	0.000298	0.00118	CcSEcCtD
Cysteamine—Nervousness—Doxorubicin—uterine cancer	0.000295	0.00117	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—HRAS—uterine cancer	0.000294	0.00528	CbGpPWpGaD
Cysteamine—Leukopenia—Epirubicin—uterine cancer	0.000294	0.00116	CcSEcCtD
Cysteamine—Convulsion—Epirubicin—uterine cancer	0.000285	0.00112	CcSEcCtD
Cysteamine—Nausea—Etoposide—uterine cancer	0.000284	0.00112	CcSEcCtD
Cysteamine—Hypertension—Epirubicin—uterine cancer	0.000284	0.00112	CcSEcCtD
Cysteamine—Anaemia—Doxorubicin—uterine cancer	0.000281	0.00111	CcSEcCtD
Cysteamine—SST—Signaling Pathways—AKR1C3—uterine cancer	0.00028	0.00503	CbGpPWpGaD
Cysteamine—Agitation—Doxorubicin—uterine cancer	0.000279	0.0011	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000278	0.0011	CcSEcCtD
Cysteamine—Discomfort—Epirubicin—uterine cancer	0.000276	0.00109	CcSEcCtD
Cysteamine—SST—Signaling Pathways—PGR—uterine cancer	0.000273	0.0049	CbGpPWpGaD
Cysteamine—Leukopenia—Doxorubicin—uterine cancer	0.000272	0.00107	CcSEcCtD
Cysteamine—Confusional state—Epirubicin—uterine cancer	0.00027	0.00107	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—AKR1C3—uterine cancer	0.000268	0.00482	CbGpPWpGaD
Cysteamine—Anaphylactic shock—Epirubicin—uterine cancer	0.000268	0.00106	CcSEcCtD
Cysteamine—Convulsion—Doxorubicin—uterine cancer	0.000263	0.00104	CcSEcCtD
Cysteamine—Nervous system disorder—Epirubicin—uterine cancer	0.000263	0.00104	CcSEcCtD
Cysteamine—Hypertension—Doxorubicin—uterine cancer	0.000262	0.00104	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—PGR—uterine cancer	0.000262	0.0047	CbGpPWpGaD
Cysteamine—Skin disorder—Epirubicin—uterine cancer	0.00026	0.00103	CcSEcCtD
Cysteamine—SST—Signaling Pathways—YWHAE—uterine cancer	0.00026	0.00468	CbGpPWpGaD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000257	0.00101	CcSEcCtD
Cysteamine—Discomfort—Doxorubicin—uterine cancer	0.000256	0.00101	CcSEcCtD
Cysteamine—Anorexia—Epirubicin—uterine cancer	0.000255	0.00101	CcSEcCtD
Cysteamine—Confusional state—Doxorubicin—uterine cancer	0.00025	0.000988	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—YWHAE—uterine cancer	0.00025	0.00448	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—FBXW7—uterine cancer	0.00025	0.00448	CbGpPWpGaD
Cysteamine—Anaphylactic shock—Doxorubicin—uterine cancer	0.000248	0.000979	CcSEcCtD
Cysteamine—Nervous system disorder—Doxorubicin—uterine cancer	0.000243	0.000961	CcSEcCtD
Cysteamine—Skin disorder—Doxorubicin—uterine cancer	0.000241	0.000951	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—FBXW7—uterine cancer	0.000239	0.0043	CbGpPWpGaD
Cysteamine—Somnolence—Epirubicin—uterine cancer	0.000238	0.000941	CcSEcCtD
Cysteamine—Anorexia—Doxorubicin—uterine cancer	0.000236	0.000934	CcSEcCtD
Cysteamine—Dyspepsia—Epirubicin—uterine cancer	0.000236	0.000932	CcSEcCtD
Cysteamine—Decreased appetite—Epirubicin—uterine cancer	0.000233	0.00092	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000231	0.000914	CcSEcCtD
Cysteamine—Fatigue—Epirubicin—uterine cancer	0.000231	0.000913	CcSEcCtD
Cysteamine—Constipation—Epirubicin—uterine cancer	0.000229	0.000905	CcSEcCtD
Cysteamine—Feeling abnormal—Epirubicin—uterine cancer	0.000221	0.000872	CcSEcCtD
Cysteamine—Somnolence—Doxorubicin—uterine cancer	0.00022	0.000871	CcSEcCtD
Cysteamine—Gastrointestinal pain—Epirubicin—uterine cancer	0.000219	0.000866	CcSEcCtD
Cysteamine—Dyspepsia—Doxorubicin—uterine cancer	0.000218	0.000862	CcSEcCtD
Cysteamine—SST—Signaling Pathways—STK11—uterine cancer	0.000218	0.00392	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—CCL2—uterine cancer	0.000217	0.0039	CbGpPWpGaD
Cysteamine—Decreased appetite—Doxorubicin—uterine cancer	0.000216	0.000851	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000214	0.000846	CcSEcCtD
Cysteamine—Fatigue—Doxorubicin—uterine cancer	0.000214	0.000844	CcSEcCtD
Cysteamine—Urticaria—Epirubicin—uterine cancer	0.000213	0.000841	CcSEcCtD
Cysteamine—Constipation—Doxorubicin—uterine cancer	0.000212	0.000838	CcSEcCtD
Cysteamine—Abdominal pain—Epirubicin—uterine cancer	0.000212	0.000837	CcSEcCtD
Cysteamine—Body temperature increased—Epirubicin—uterine cancer	0.000212	0.000837	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—STK11—uterine cancer	0.000209	0.00376	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—CCL2—uterine cancer	0.000208	0.00374	CbGpPWpGaD
Cysteamine—Feeling abnormal—Doxorubicin—uterine cancer	0.000204	0.000807	CcSEcCtD
Cysteamine—SST—Signaling Pathways—SOCS3—uterine cancer	0.000204	0.00367	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000203	0.000801	CcSEcCtD
Cysteamine—Hypersensitivity—Epirubicin—uterine cancer	0.000197	0.00078	CcSEcCtD
Cysteamine—Urticaria—Doxorubicin—uterine cancer	0.000197	0.000778	CcSEcCtD
Cysteamine—Body temperature increased—Doxorubicin—uterine cancer	0.000196	0.000774	CcSEcCtD
Cysteamine—Abdominal pain—Doxorubicin—uterine cancer	0.000196	0.000774	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—SOCS3—uterine cancer	0.000196	0.00352	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CDKN2B—uterine cancer	0.000196	0.00351	CbGpPWpGaD
Cysteamine—Asthenia—Epirubicin—uterine cancer	0.000192	0.000759	CcSEcCtD
Cysteamine—SST—Signaling Pathways—IGF1R—uterine cancer	0.00019	0.00341	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—CXCL8—uterine cancer	0.000189	0.0034	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CDKN2B—uterine cancer	0.000187	0.00337	CbGpPWpGaD
Cysteamine—Diarrhoea—Epirubicin—uterine cancer	0.000183	0.000724	CcSEcCtD
Cysteamine—Hypersensitivity—Doxorubicin—uterine cancer	0.000183	0.000722	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—IGF1R—uterine cancer	0.000182	0.00327	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—CXCL8—uterine cancer	0.000181	0.00326	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—SMAD3—uterine cancer	0.000179	0.00321	CbGpPWpGaD
Cysteamine—Asthenia—Doxorubicin—uterine cancer	0.000178	0.000703	CcSEcCtD
Cysteamine—Dizziness—Epirubicin—uterine cancer	0.000177	0.0007	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CXCL8—uterine cancer	0.000172	0.00308	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—SMAD3—uterine cancer	0.000171	0.00308	CbGpPWpGaD
Cysteamine—Vomiting—Epirubicin—uterine cancer	0.00017	0.000673	CcSEcCtD
Cysteamine—SST—Signaling Pathways—FGFR2—uterine cancer	0.00017	0.00306	CbGpPWpGaD
Cysteamine—Diarrhoea—Doxorubicin—uterine cancer	0.00017	0.00067	CcSEcCtD
Cysteamine—Rash—Epirubicin—uterine cancer	0.000169	0.000667	CcSEcCtD
Cysteamine—Dermatitis—Epirubicin—uterine cancer	0.000169	0.000667	CcSEcCtD
Cysteamine—Headache—Epirubicin—uterine cancer	0.000168	0.000663	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—CXCL8—uterine cancer	0.000165	0.00296	CbGpPWpGaD
Cysteamine—Dizziness—Doxorubicin—uterine cancer	0.000164	0.000648	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—FGFR2—uterine cancer	0.000163	0.00293	CbGpPWpGaD
Cysteamine—Nausea—Epirubicin—uterine cancer	0.000159	0.000629	CcSEcCtD
Cysteamine—Vomiting—Doxorubicin—uterine cancer	0.000158	0.000623	CcSEcCtD
Cysteamine—Rash—Doxorubicin—uterine cancer	0.000156	0.000618	CcSEcCtD
Cysteamine—Dermatitis—Doxorubicin—uterine cancer	0.000156	0.000617	CcSEcCtD
Cysteamine—Headache—Doxorubicin—uterine cancer	0.000155	0.000614	CcSEcCtD
Cysteamine—Nausea—Doxorubicin—uterine cancer	0.000147	0.000582	CcSEcCtD
Cysteamine—SST—Signaling Pathways—ESR1—uterine cancer	0.000146	0.00262	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—ESR1—uterine cancer	0.00014	0.00251	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—NRAS—uterine cancer	0.000138	0.00247	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—NRAS—uterine cancer	0.000132	0.00237	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CCL2—uterine cancer	0.000128	0.0023	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CCL2—uterine cancer	0.000123	0.00221	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—PIK3CA—uterine cancer	0.00012	0.00215	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—KRAS—uterine cancer	0.000119	0.00213	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CA—uterine cancer	0.000115	0.00207	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—KRAS—uterine cancer	0.000114	0.00204	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PIK3CA—uterine cancer	0.000109	0.00196	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—ERBB2—uterine cancer	0.000107	0.00192	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CA—uterine cancer	0.000104	0.00188	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—ERBB2—uterine cancer	0.000103	0.00184	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CXCL8—uterine cancer	0.000101	0.00182	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—HRAS—uterine cancer	0.000101	0.00181	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CDKN1B—uterine cancer	9.9e-05	0.00178	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—AKT1—uterine cancer	9.8e-05	0.00176	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CXCL8—uterine cancer	9.72e-05	0.00175	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—HRAS—uterine cancer	9.66e-05	0.00174	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CDKN1B—uterine cancer	9.49e-05	0.00171	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—AKT1—uterine cancer	9.39e-05	0.00169	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CTNNB1—uterine cancer	9.36e-05	0.00168	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PTEN—uterine cancer	9.12e-05	0.00164	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CTNNB1—uterine cancer	8.97e-05	0.00161	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—AKT1—uterine cancer	8.9e-05	0.0016	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PTEN—uterine cancer	8.74e-05	0.00157	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—EP300—uterine cancer	8.7e-05	0.00156	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—AKT1—uterine cancer	8.53e-05	0.00153	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—EP300—uterine cancer	8.34e-05	0.0015	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—VEGFA—uterine cancer	8.24e-05	0.00148	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—NRAS—uterine cancer	8.14e-05	0.00146	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—VEGFA—uterine cancer	7.9e-05	0.00142	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—NRAS—uterine cancer	7.8e-05	0.0014	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—KRAS—uterine cancer	7e-05	0.00126	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—KRAS—uterine cancer	6.71e-05	0.00121	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CA—uterine cancer	6.43e-05	0.00116	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TP53—uterine cancer	6.22e-05	0.00112	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CA—uterine cancer	6.17e-05	0.00111	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TP53—uterine cancer	5.97e-05	0.00107	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HRAS—uterine cancer	5.95e-05	0.00107	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—HRAS—uterine cancer	5.71e-05	0.00103	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—AKT1—uterine cancer	5.26e-05	0.000944	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—AKT1—uterine cancer	5.04e-05	0.000905	CbGpPWpGaD
